From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding.


Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
01 2022
Historique:
received: 01 07 2021
accepted: 24 10 2021
pubmed: 27 11 2021
medline: 23 2 2022
entrez: 26 11 2021
Statut: ppublish

Résumé

In 2019, the Innovative Medicines Initiative (IMI) funded the ConcePTION project-Building an ecosystem for better monitoring and communicating safety of medicines use in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation-with the vision that there is a societal obligation to rapidly reduce uncertainty about the safety of medication use in pregnancy and breastfeeding. The present paper introduces the set of concepts used to describe the European data sources involved in the ConcePTION project and illustrates the ConcePTION Common Data Model (CDM), which serves as the keystone of the federated ConcePTION network. Based on data availability and content analysis of 21 European data sources, the ConcePTION CDM has been structured with six tables designed to capture data from routine healthcare, three tables for data from public health surveillance activities, three curated tables for derived data on population (e.g., observation time and mother-child linkage), plus four metadata tables. By its first anniversary, the ConcePTION CDM has enabled 13 data sources to run common scripts to contribute to major European projects, demonstrating its capacity to facilitate effective and transparent deployment of distributed analytics, and its potential to address questions about utilization, effectiveness, and safety of medicines in special populations, including during pregnancy and breastfeeding, and, more broadly, in the general population.

Identifiants

pubmed: 34826340
doi: 10.1002/cpt.2476
pmc: PMC9299060
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

321-331

Subventions

Organisme : Innovative Medicines Initiative 2 Joint Undertaking
ID : 821520

Informations de copyright

© 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):998-1005
pubmed: 28657162
PLoS One. 2016 Aug 31;11(8):e0160648
pubmed: 27580049
BMJ Open. 2014 Feb 17;4(2):e004365
pubmed: 24534260
Int J Med Inform. 2002 Nov 12;65(3):225-41
pubmed: 12414020
Int Breastfeed J. 2015 Oct 28;10:28
pubmed: 26516340
JAMA Netw Open. 2020 Aug 3;3(8):e2015094
pubmed: 32865574
Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1-11
pubmed: 21182150
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
BMC Pediatr. 2013 Nov 19;13:192
pubmed: 24252465
BMJ. 2011 Jul 12;343:d3908
pubmed: 21750072
J Am Med Inform Assoc. 2014 Jul-Aug;21(4):578-82
pubmed: 24821743
BMJ Open. 2021 Jun 28;11(6):e047859
pubmed: 34183346
Clin Pharmacol Ther. 2020 Apr;107(4):827-833
pubmed: 31330042
J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60
pubmed: 22037893
Am J Public Health. 2019 Nov;109(11):1482-1483
pubmed: 31577483
Pharmacoeconomics. 2021 Mar;39(3):275-285
pubmed: 33336320
Philos Ethics Humanit Med. 2019 Sep 6;14(1):11
pubmed: 31492178
Clin Pharmacol Ther. 2020 Aug;108(2):228-235
pubmed: 32243569
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
Vaccine. 2020 Dec 22;38 Suppl 2:B56-B64
pubmed: 31677950
Diabetologia. 2017 Sep;60(9):1691-1703
pubmed: 28573394
CMAJ. 2017 Apr 18;189(15):E560-E568
pubmed: 28420680
Am J Obstet Gynecol. 2014 Dec;211(6):690.e1-11
pubmed: 24912093
N Engl J Med. 2009 Aug 13;361(7):645-7
pubmed: 19635947
Stud Fam Plann. 2014 Sep;45(3):301-14
pubmed: 25207494

Auteurs

Nicolas H Thurin (NH)

Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, Bordeaux, France.

Romin Pajouheshnia (R)

Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

Giuseppe Roberto (G)

Agenzia regionale di sanità della Toscana, Florence, Italy.

Caitlin Dodd (C)

PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.

Giulia Hyeraci (G)

Agenzia regionale di sanità della Toscana, Florence, Italy.

Claudia Bartolini (C)

Agenzia regionale di sanità della Toscana, Florence, Italy.

Olga Paoletti (O)

Agenzia regionale di sanità della Toscana, Florence, Italy.

Hedvig Nordeng (H)

PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.

Helle Wallach-Kildemoes (H)

PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.

Vera Ehrenstein (V)

Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.

Elena Dudukina (E)

Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.

Thomas MacDonald (T)

MEMO Research, School of Medicine, University of Dundee, Dundee, UK.

Giorgia De Paoli (G)

MEMO Research, School of Medicine, University of Dundee, Dundee, UK.

Maria Loane (M)

Institute of Nursing and Health Research, Ulster University, Newtownabbey, UK.

Christine Damase-Michel (C)

INSERM, CERPOP: SPHERE, CIC 1436, Université de Toulouse, Toulouse, France.

Anna-Belle Beau (AB)

INSERM, CERPOP: SPHERE, CIC 1436, Université de Toulouse, Toulouse, France.

Cécile Droz-Perroteau (C)

Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, Bordeaux, France.

Régis Lassalle (R)

Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, Bordeaux, France.

Jorieke Bergman (J)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Karin Swart (K)

PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.

Tania Schink (T)

Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany.

Clara Cavero-Carbonell (C)

Fundació per al Foment de la Investigació Sanitaria i Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.

Laia Barrachina-Bonet (L)

Fundació per al Foment de la Investigació Sanitaria i Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.

Ainhoa Gomez-Lumbreras (A)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Universitat Autònoma de Barcelona, Bellaterra, Spain.

Maria Giner-Soriano (M)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Universitat Autònoma de Barcelona, Bellaterra, Spain.

María Aragón (M)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Universitat Autònoma de Barcelona, Bellaterra, Spain.

Amanda J Neville (AJ)

IMER Registry (Emila Romagna Registry of Birth Defects), Center of Epidemiology for Clinical Research, University of Ferrara, Ferrara, Italy.

Aurora Puccini (A)

Drug Policy Service, Emilia Romagna Region Health Authority, Bologna, Italy.

Anna Pierini (A)

Epidemiology of Rare Diseases and Congenital Anomalies Unit, National Research Council-Institute of Clinical Physiology (CNR-IFC), Pisa, Italy.

Valentina Ientile (V)

Department of Biomedical and Dental Sciences and Morpho-functional Imaging, University of Messina, Messina, Italy.

Gianluca Trifirò (G)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Anke Rissmann (A)

Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty, Otto-von-Guericke-University, Magdeburg, Germany.

Maarit K Leinonen (MK)

Finnish Institute for Health and Welfare, Helsinki, Finland.

Visa Martikainen (V)

Finnish Institute for Health and Welfare, Helsinki, Finland.

Sue Jordan (S)

Faculty of Health and Life Science, Swansea University, Swansea, UK.

Daniel Thayer (D)

Faculty of Health and Life Science, Swansea University, Swansea, UK.

Ieuan Scanlon (I)

Faculty of Health and Life Science, Swansea University, Swansea, UK.

Mary E Georgiou (ME)

Glaxosmithkline, Stevenage, UK.

Marianne Cunnington (M)

Glaxosmithkline, Stevenage, UK.

Morris Swertz (M)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Miriam Sturkenboom (M)

Department Datascience and Biostatistics, University Medical Center Utrecht, Utrecht, The Netherlands.

Rosa Gini (R)

Agenzia regionale di sanità della Toscana, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH